Roche's "Evrysdi (Risdiplam)," the second treatment for spinal muscular atrophy (SMA) in Korea, signaled its launch after about a year of approval. With the differentiation of the only PO drug and low prices, fierce competition in the SMA market was predicted.

"Evrysdi is the first oral drug among SMA treatments and is applicable to patients with difficulty in treating SMA, and has confirmed its effectiveness and safety in patients of a wide range of ages and types," Roche Korea stressed at an Evrysdi meeting on the 5th. Evrysdi (Risdiplam) is a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older. Spinal muscular atrophy (SMA) is a rare gene